180,000 Shares in Merus (NASDAQ:MRUS) Bought by Impax Asset Management Group plc

Impax Asset Management Group plc purchased a new stake in Merus (NASDAQ:MRUS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 180,000 shares of the biotechnology company’s stock, valued at approximately $7,569,000. Impax Asset Management Group plc owned approximately 0.26% of Merus at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. HealthInvest Partners AB raised its position in shares of Merus by 23.3% during the 4th quarter. HealthInvest Partners AB now owns 62,521 shares of the biotechnology company’s stock worth $2,619,000 after acquiring an additional 11,834 shares in the last quarter. TimesSquare Capital Management LLC raised its holdings in Merus by 21.6% during the fourth quarter. TimesSquare Capital Management LLC now owns 331,195 shares of the biotechnology company’s stock worth $13,927,000 after purchasing an additional 58,760 shares in the last quarter. State of New Jersey Common Pension Fund D raised its holdings in Merus by 29.0% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 48,268 shares of the biotechnology company’s stock worth $2,030,000 after purchasing an additional 10,842 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Merus by 10.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,517 shares of the biotechnology company’s stock worth $610,000 after buying an additional 1,398 shares during the last quarter. Finally, KBC Group NV grew its position in shares of Merus by 4,583.6% in the 4th quarter. KBC Group NV now owns 57,234 shares of the biotechnology company’s stock valued at $2,407,000 after buying an additional 56,012 shares during the last quarter. 96.14% of the stock is owned by hedge funds and other institutional investors.

Merus Stock Down 1.3 %

Shares of NASDAQ:MRUS opened at $46.75 on Tuesday. The company has a market cap of $3.20 billion, a P/E ratio of -11.84 and a beta of 1.11. Merus has a 52 week low of $37.77 and a 52 week high of $61.61. The company has a 50-day moving average price of $41.80 and a 200 day moving average price of $46.89.

Analysts Set New Price Targets

Several equities analysts have issued reports on MRUS shares. Guggenheim restated a “buy” rating on shares of Merus in a research note on Wednesday, February 12th. Citigroup upped their target price on Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research report on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and set a $85.00 price target on shares of Merus in a research report on Monday, December 2nd. Wells Fargo & Company began coverage on Merus in a report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 target price on shares of Merus in a report on Monday, December 9th. One analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Merus currently has an average rating of “Buy” and an average price target of $85.92.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.